City. The role of Krebs cycle inhibition by fluoroacetate. Arch Neurol…
페이지 정보
본문
City. The role of Krebs cycle inhibition by fluoroacetate. Arch Neurol. 1970;23:155?0. 63. St han F, Etienne MC, Wallays C, Milano G, Clergue F. Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicities. Am J Med. 1995;99:685?. 64. Yeh KH, Cheng AL. High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy. Br J Cancer. 1997;75:464?. 65. Okeda R, Karakama T, Kimura S, Toizumi S, Mitsushima T, Yokoyama Y. Neuropathologic study on chronic neurotoxicity of 5-fluorouracil and its masked compounds in dogs. Acta Neuropathol. 1984;63:334?3. 66. Rengelshausen J, Hull WE, Schwenger V, G gelmann C, Walter-Sack I, Bommer J. Pharmacokinetics of 5-fluorouracil and its catabolites determined by 19F nuclear magnetic resonance spectroscopy for a patient on chronic hemodialysis. Am J Kidney Dis. 2002;39:E10. 67. Izzedine H, Etienne-Grimaldi MC, Ren N, Vignot S, Milano G. Pharmacokinetics of sunitinib in hemodialysis. Ann Oncol. 2009;20:190?. 68. Thiery-Vuillemin PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/15501003 A, Montange D, Kalbacher E, Maurina T, Nguyen T, Royer B, et al. Impact of sunitinib pharmacokinetic monitoring in a patient with metastatic renal cell carcinoma undergoing hemodialysis. Ann Oncol. 2011;22:2152?. 69. Pappas P, Karavasilis V, Briasoulis E, Pavlidis N, Marselos M. Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. Cancer Chemother Pharmacol. 2005;56:358?0. 70. Kennoki T, Kondo T, Kimata N, Murakami J, Ishimori I, Nakazawa H, et al. Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center. Jpn J Clin Oncol. 2011;41:647?5. 71. Togashi Y, Masago K, Fukudo M, Terada T, Ikemi Y, Kim YH, et al. Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysis. J Thorac Oncol. 2010;5:601?. 72. Masini C, Sabbatini R, Porta C, Procopio G, Di Lorenzo G, Onofri A, et al. Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. BJU Int. 2012;110:692?. 73. Hidalgo M. Erlotinib: preclinical investigations. Oncology (Williston Park). 2003;17:11?. 74. Ozdemir E, Koc Y, Kansu E. Nelfinavir (Mesylate) Successful treatment of chronic myeloid leukemia with imatinib mesylate in a patient with chronic renal failure on hemodialysis. Am J Hematol. 2006;81:474.75. Rey PM, Villavicencio H. Sorafenib: tolerance in patients on chronic hemodialysis: a single-center experience. Oncology. 2008;74:245?. 76. Djavan B, Shariat S, Ghawidel K, G en-Marberger K, Remzi M, Kovarik J, et al. Impact of chronic dialysis on serum PSA, free PSA, and free/total PSA ratio: is prostate cancer detection compromised in patients receiving longterm dialysis? Urology. 1999;53:1169?4. 77. Kurata H, Yoshiya N, Ikarashi H, Kaneko T, Kodama S, Tanaka K, et al. Pharmacokinetics of carboplatin in a patient under hemodialysis. Gan To Kagaku Ryoho. 1994;21:547?0. 78. Suzuki S, Koide M, Sakamoto S, Matsuo T. Pharmacokinetics of carboplatin and etoposide in a haemodialysis patient with Merkel-cell carcinoma. Nephrol Dial Transplant. 1997;12:137?0. 79. Furuya Y, Takihana Y, Araki I, Tanabe N, Takeda M. Pharmacokinetics of paclitaxel and carboplatin in a hemodialysis patient with metastatic urothelial carcinoma--a case report. Gan To Kagaku Ryoho. 2003;30:1017?0. 80. Takezawa K, Okamoto I,.
댓글목록
등록된 댓글이 없습니다.